HomeCompareAINT vs MRK

AINT vs MRK: Dividend Comparison 2026

AINT yields 8.25% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $23.2K in total portfolio value· pulled ahead in Year 6
10 years
AINT
AINT
● Live price
8.25%
Share price
$24.24
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.5K
Annual income
$1,390.15
Full AINT calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — AINT vs MRK

📍 MRK pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAINTMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AINT + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AINT pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AINT
Annual income on $10K today (after 15% tax)
$701.32/yr
After 10yr DRIP, annual income (after tax)
$1,181.63/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $7,415.09/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AINT + MRK for your $10,000?

AINT: 50%MRK: 50%
100% MRK50/50100% AINT
Portfolio after 10yr
$46.1K
Annual income
$5,751.97/yr
Blended yield
12.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

AINT
No analyst data
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AINT buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAINTMRK
Forward yield8.25%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$34.5K$57.7K
Annual income after 10y$1,390.15$10,113.78
Total dividends collected$11.1K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AINT vs MRK ($10,000, DRIP)

YearAINT PortfolioAINT Income/yrMRK PortfolioMRK Income/yrGap
1$11,525$825.08$11,213$373.04+$312.00AINT
2$13,221$888.71$12,667$512.06+$554.00AINT
3$15,099$952.75$14,439$708.14+$660.00AINT
4$17,173$1,016.92$16,640$988.16+$533.00AINT
5$19,456$1,080.93$19,432$1,394.07+$24.00AINT
6← crossover$21,962$1,144.52$23,057$1,992.90$1.1KMRK
7$24,707$1,207.44$27,889$2,894.79$3.2KMRK
8$27,706$1,269.48$34,518$4,286.29$6.8KMRK
9$30,976$1,330.44$43,912$6,494.35$12.9KMRK
10$34,534$1,390.15$57,714$10,113.78$23.2KMRK

AINT vs MRK: Complete Analysis 2026

AINTStock

AINT seeks long-term capital appreciation and absolute returns by employing a dollar-neutral strategy, taking long and short positions in large-cap US stocks from the S&P 500 (SPX), determined by a proprietary, adaptive AI Model. The model continuously ranks all 500 SPX stocks daily, integrating conventional and professional wisdom, fundamental signals, regulatory interpretations, NLP-extracted financial data, and advanced machine learning to provide dynamic stock rankings. Based on these rankings, the fund selects and weights the 1014 highest- and lowest-ranked stocks, respectively, with consideration to regulatory restrictions. The fund aims to balance long and short exposures and focus on relative performance and not market direction. Leverage may be used, increasing both gains and losses. The sub-adviser oversees the AI model for technical issues but does not alter outputs. Actual fund performance may differ from model results due to timing, fees, and cash holdings for operations.

Full AINT Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this AINT vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AINT vs SCHDAINT vs JEPIAINT vs OAINT vs KOAINT vs MAINAINT vs JNJAINT vs ABBVAINT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.